Skip to main content
All lobbying filings

Ardelyx, Inc.

Ardelyx, Inc. filed a Q2 amendment for Ardelyx, Inc. on July 16, 2026.

Lobbying for Ardelyx, Inc.

As filed: ARDELYX, INC. for ARDELYX, INC.

All filings by Ardelyx, Inc. · Everything Ardelyx, Inc. has reported

 Filing · LD-2 quarterly report Q2 amendment
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 16, 2026
Expenses
$500,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem